JGJames Godfrey

James Godfrey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Godfrey has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas

    by Paolo Lopedote, Avyakta Kallam, Alexey V Danilov, Tycel J. Phillips, Geoffrey Shouse, Brian Sworder, Azra Borogovac, Yan Liu, Joo Y. Y Song, Alex F. Herrera, et al.

    Patients with relapsed/refractory (r/r) central nervous system lymphoma (CNSL) have poor survival with currently available treatments. Early reports suggest antibody-based treatments such as bispecific antibodies and antibody-drug conjugates can penetrate the blood-brain barrier and induce clinical responses in r/r CNSL. In this study, we retrospectively evaluated the safety and activity of glofitamab plus polatuzumab vedotin in 9 r/r CNSL patients treated at our institution, including high-risk subtypes such as chemorefractory Burkitt lymphoma and TP53-mutant Mantle cell lymphoma. Here, we observed a 100% overall and 89% complete response rate. Responses occurred in patients with brain parenchymal and leptomeningeal involvement, with rapid clearance of lymphoma cells from the cerebrospinal fluid within days of treatment as assessed by flow cytometry. Safety aligned with the known toxicity profile of the regimen in patients with systemic lymphomas. These data indicate glofitamab with polatuzumab vedotin is capable of safely inducing deep and rapid clinical remissions in r/r CNSL, including in high-risk histological and molecular subtypes. Future prospective evaluation of the regimen for r/r CNSL is warranted given the unmet need of this population.

  • LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma

    by Sravya Tumuluru, Alan Cooper, Yanwen Jiang, Connie Lee Batlevi, Will Harris, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, et al.

    PURPOSE: Genetic classification may advance precision medicine in diffuse large B-cell lymphoma (DLBCL), but existing tools like LymphGen (LG) are limited by complexity and incomplete classification and do not incorporate nongenetic features that affect disease biology and therapeutic outcomes. To address these limitations, we developed LG-sig (LGsig), a gene expression–based platform that classifies all DLBCLs and harmonizes both genetic and nongenetic dimensions of the disease. METHODS: LGsig was built on the distinct subtype-specific gene expression signature of each LG class using paired genomic and transcriptomic data (National Cancer Institute/British Columbia Cancer Agency; N = 764). Model development was restricted to DLBCLs classified into MYD88 L265P and CD79B mutations (MCD), BCL6 translocation and NOTCH2 mutations (BN2), EZH2 mutations and BCL2 translocation (EZB), or SGK1 and TET2 mutations (ST2). Gene features were selected by differential gene expression, with 294 genes being optimal for classification using a nearest shrunken centroid classifier. LGsig classifications were designated as MCDsig , BN2sig , ST2sig , and EZBsig . The final model was applied to RNAseq from archival samples from the POLARIX trial (N = 678) to assess outcomes after polatuzumab vedotin-R-CHP (pola-R-CHP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for each LGsig subtype. RESULTS: LGsig accurately identified LG subtypes using transcriptional data alone and extended assignments to all previously LG-unclassified cases. Importantly, LG-unclassified DLBCLs reassigned by LGsig mirrored the transcriptional and clinical features of their corresponding LG counterparts, supporting their reclassification. In addition, LGsig reassigned LG A53 DLBCLs, characterized by aneuploidy and TP53 alterations, into more biologically and therapeutically relevant LGsig clusters. Finally, LGsig improved the performance of LG as a biomarker in the POLARIX study, by identifying distinct DLBCL subtypes exhibiting a survival benefit with pola-R-CHP over R-CHOP in both LG-classified and LG-unclassified cases. CONCLUSION: LGsig expands molecular classification beyond current genetic classifiers in DLBCL by integrating both genetic and transcriptional dimensions of the disease to better inform subtype-specific therapeutic strategies.


  • Open Access

    LymphGen-Sig: Integrating genetic and transcriptional states to predict therapeutic response in DLBCL

    by Sravya Tumuluru, Alan Cooper, Yanwen Jiang, Connie Lee Batlevi, Will Harris, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, et al.

    Purpose Genetic classification may advance precision medicine in diffuse large B-cell lymphoma (DLBCL), but existing tools like LymphGen (LG) are limited by complexity, incomplete classification, and do not incorporate non-genetic features that impact disease biology and therapeutic outcomes. To address these limitations, we developed LymphGen-sig (LGsig), a gene expression-based platform that classifies all DLBCLs and harmonizes both genetic and non-genetic dimensions of the disease. Methods LGsig was built on the distinct subtype-specific gene expression signature of each LG class using paired genomic and transcriptomic data (NCI/BCCA; n=764). Model development was restricted to DLBCLs classified into MCD, BN2, EZB, or ST2. Gene features were selected by differential gene expression, with 294 genes being optimal for classification using a nearest shrunken centroid classifier. LGsig classifications were designated MCDsig, BN2sig, ST2sig, and EZBsig. The final model was applied to RNAseq from archival samples from the POLARIX trial (n=678) to assess outcomes after polatuzumab vedotin-R-CHP (pola-R-CHP) or R-CHOP for each LGsig subtype. Results LGsig accurately identified LG subtypes using transcriptional data alone, and extended assignments to all previously LG-unclassified cases. Importantly, LG-unclassified DLBCLs reassigned by LGsig, mirrored the transcriptional and clinical features of their corresponding LG counterparts, supporting their reclassification. Additionally, LGsig reassigned LG A53 DLBCLs, characterized by aneuploidy and TP53 alterations, into more biologically and therapeutically-relevant LGsig clusters. Lastly, LGsig improved the performance of LG as a biomarker in the POLARIX study, by identifying distinct DLBCL subtypes exhibiting a survival benefit with pola-R-CHP over R-CHOP in both LG-classified and LG-unclassified cases. Conclusion LGsig expands molecular classification beyond current genetic classifiers in DLBCL by integrating both genetic and transcriptional dimensions of the disease to better inform subtype-specific therapeutic strategies.


  • Open Access

    Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration

    by Lei Gao, Avyakta Kallam, Geoffrey Shouse, John H. Baird, Stacy Pak, Yue Qin, Joo Y. Song, Guido Marcucci, Lucy Y. Ghoda, Claire Guillen, et al.

    Polatuzumab vedotin (pola) is a CD79B-targeting antibody-drug conjugate with significant clinical activity in systemic diffuse large B-cell lymphoma. However, the ability of pola to penetrate the blood-brain barrier (BBB) and induce responses in central nervous system (CNS) lymphoma (CNSL) is unknown. Since other antibody-based therapies can partially penetrate the BBB to induce clinical responses in CNSL and other CNS malignancies, we hypothesized that pola would also partially penetrate the BBB, which could support its evaluation in future CNSL clinical trials. To test this hypothesis, we first evaluated the preclinical efficacy of pola in primary and secondary CNSL xenografts, where we observed that pola significantly decreased CNS tumor burden and prolonged survival in mice. To extend these findings, we compiled a clinical case series of 3 patients with CNSL treated with pola-based treatment. Here, on-treatment cerebrospinal fluid (CSF) samples revealed pola CSF drug concentrations exceeding its established 50% inhibitory concentration, with CSF drug levels being 0.56% to 1.31% of those in plasma. Interestingly, 2 of the 3 patients with CNSL achieved a complete response to pola-based treatment. In summary, these data indicate pola is effective against preclinical CNSL models and can partially penetrate the BBB in patients with CNSL, which together provide support for the evaluation of pola-based treatment in future clinical trials of primary and secondary CNSL.


  • Open Access

    A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL

    by Kirk Cahill, James Godfrey, Chadi Nabhan, Justin Kline, Peter A. Riedell, Kenneth S. Cohen, Sunil Narula, Theodore G. Karrison, Jessica Robertson, Reem Karmali, et al.

    In patients with diffuse large B-cell lymphoma (DLBCL), concurrent deregulation of MYC and BCL2 confers inferior outcomes following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). DA–EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) produces favorable results in patients with dual MYC and BCL2 rearrangement (double-hit lymphoma [DHL]), but there are limited prospective data in both DHL and DLBCL with dual protein overexpression of Myc and Bcl2 (double-expressor lymphoma [DEL]). Lenalidomide (LEN) may enhance the response in MYC-driven lymphomas, prompting this investigator-initiated multicenter phase 1/2 study evaluating LEN with DA–EPOCH-R in adults with newly diagnosed DHL and DEL. Fifty-five patients (DHL, 23; DEL, 32) were enrolled and treated. Patients had a median age of 65 years (range, 25-82), International Prognostic Index ≥3 in 69% (38/55), and stage III/IV in 91% (50/55). The overall response rate was 90.9%, with a complete response rate of 83.6%. With a median follow-up of 3.4 years, the primary end point efficacy criterion was met with 1- and 2-year progression-free survival (PFS) rates of 85.5% and 78.2%, respectively. The 2-year overall survival was 83.6%. The most common adverse events (grade ≥3) were neutropenia (67%), anemia (67%), thrombocytopenia (49%), and neutropenic fever (35%). There were no grade 5 events. Second primary malignancy occurred in 6 patients (11%). LEN with DA–EPOCH-R for patients with DEL and DHL has a high response rate, encouraging survival, and met the primary PFS efficacy criterion. A randomized trial of DA–EPOCH-R with and without LEN would be needed to determine the specific benefit of LEN. This trial was registered at www.ClinicalTrials.gov as #NCT02213913.


  • Top Cited Papers
    Open Access

    Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response

    by Sravya Tumuluru, James K. Godfrey, Alan Cooper, Jovian Yu, Xiufen Chen, Brendan W. MacNabb, Girish Venkataraman, Yuanyuan Zha, Benedikt Pelzer, Joo Song, et al.

    Most patients with diffuse large B-cell lymphoma (DLBCL) treated with immunotherapies such as bispecific antibodies (BsAbs) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the need for a deeper understanding of mechanisms that regulate the immune environment and response to treatment. Here, an integrative multiomics approach was applied to multiple large independent data sets to characterize DLBCL immune environments and to define their association with tumor cell–intrinsic genomic alterations and outcomes to CD19-directed CAR T-cell and CD20 × CD3 BsAb therapies. This approach effectively segregated DLBCLs into 4 immune quadrants (IQs) defined by cell-of-origin and immune-related gene set expression scores. These quadrants consisted of activated B cell–like (ABC) hot, ABC cold, germinal center B cell–like (GCB) hot, and GCB cold DLBCLs. Recurrent genomic alterations were enriched in each IQ, suggesting that lymphoma cell-intrinsic alterations contribute significantly to orchestrating unique DLBCL immune environments. For instance, SOCS1 loss-of-function mutations were significantly enriched among GCB hot DLBCLs, identifying a putative subset of inflamed DLBCLs that may be inherently susceptible to immunotherapy. In patients with relapsed/refractory DLBCL, DLBCL-IQ assignment correlated significantly with clinical benefit with a CD20 × CD3 BsAb (N = 74), but not with CD19-directed CAR T cells (Stanford, N = 51; Memorial Sloan Kettering Cancer Center, N = 69). Thus, DLBCL-IQ provides a new framework to conceptualize the DLBCL immune landscape and suggests the endogenous immune environment has a more significant impact on outcomes to BsAb than CAR T-cell treatment.


  • Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

    by James K. Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, et al.

    Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS.


  • Open Access

    Figure S3 from T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses

    by Xiufen Chen, Jovian Yu, Girish Venkataraman, Sonali M. Smith, Mengjie Chen, Alan Cooper, Sravya Tumuluru, Joshua D. Brody, James Godfrey, Justin Kline

    Supplemental Figure S3. Single cell profiles of selected genes across T cell clusters from all samples

  • Open Access

    Figure S2 from T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses

    by Xiufen Chen, Jovian Yu, Girish Venkataraman, Sonali M. Smith, Mengjie Chen, Alan Cooper, Sravya Tumuluru, Joshua D. Brody, James Godfrey, Justin Kline

    Supplemental Figure S2. Proportions of all clusters in RLT and cHL samples

  • Open Access

    Figure S2 from T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses

    by Xiufen Chen, Jovian Yu, Girish Venkataraman, Sonali M. Smith, Mengjie Chen, Alan Cooper, Sravya Tumuluru, Joshua D. Brody, James Godfrey, Justin Kline

    Supplemental Figure S2. Proportions of all clusters in RLT and cHL samples